Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NXXQfWJ5TnWwY4Tpc44hSXO|YYm= MXmyJO69VQ>? M2LBSlEhcA>? NHzPXVVqdmirYnn0d{B1cGViTD3EU3BCKCh{MNMg{txOMS2rbnT1Z4VlKHS{YX7zbYVvfCCHUluxM|IheGixc4Doc5J6dGG2aX;uxsA> NVnEbI0{OjZ|NkOxPVE>
C2C12 MWXGeY5kfGmxbjDBd5NigQ>? MW[xxsDPxGdxbXy= NVj4Z|J5OcLiaB?= MkTzZYJwdGm|aHXzJIN6fG:taX7lJJJmdGWjc3Wg[pJwdSCFMlOxNkBugW:2dXLldy=> M3jEeVI3OjlzMke5
MEFs WT NFXqW4RHfW6ldHnvckBCe3OjeR?= NX36cpRrPcLizszN MYSyNEBucW5? NFzJe4Zk[XW|ZYOgdoV{cWSnboSg[Y57gW2nczDzeYNpKGG|IF7BS3QuT0[SLDD0c{BlcW[odYPlJIJi[2tidH:geIhmKEWU M4KzSVI3OTl4MEKz
MEFs VAMP7 KO NE\F[2ZHfW6ldHnvckBCe3OjeR?= NVTHNoI3PcLizszN NGrxSJUzOCCvaX6= NUfQVIxI[2G3c3XzJJJme2mmZX70JIVvgnmvZYOgd5VkcCCjczDORWdVNUeIUDygeI8h\GmoZoXz[UBj[WOtIITvJJRp\SCHUh?= NGW5XW4zPjF7NkCyNy=>
SMCs NGH0[HRHfW6ldHnvckBCe3OjeR?= NEHyPFAyOMLiwsXnM41t NFnWbI0xNTF{IHi= NXPqWHpTTE2VTx?= M3\qepNpd3e|IHGgeJJmdmRidH;3ZZJleyCjIHjp[4hmeiClb37j[Y51emG2aX;uJI9nKHSqZTDFVk9UWiCwZYT3c5JsKGmwIITo[UBx\XKrboXjcIVieiCjcnXhxsA> MoDGNlYyPzJyOEC=
SMCs NVj3dFFzTnWwY4Tpc44hSXO|YYm= NGD0UmgyOMLiwsXnM41t NWL1clZFOC1zMjDo MmDQSG1UVw>? NUHUeoJO[2G3c3XzJIEhfHKjboPp[Y51KEOjMjxCpJJmdGWjc3Wg[pJwdSC2aHWgSXIwW1MEoB?= M4fsOlI3OTd{MEiw
HEMC-1 NHrkPXpHfW6ldHnvckBCe3OjeR?= MmXhNE4yyqEEtXevcYw> NX;1UHVMOjUEoHi= NGSyRZVk[XW|ZYOgZUBpcWeqZYKgbY5pcWKrdH;yfUBm\m[nY4Sgc44h\XixY4n0c5NqeyC2aHHuJI5w[2:mYYrvcIU> MWqyOVk4Ojd3OR?=
HUVEC MV;GeY5kfGmxbjDBd5NigQ>? NIrQcY0yOMLizszN Ml65NeKhcA>? NFK2eJhFVVOR MVThZo9tcXOqZYOgbJlxd3irYT3pcoR2[2WmIILlcIVie2Vib3[gRXRRKG[{b32gZZBq[2GuIHHu[EBj[XOxbHH0[ZJidCC|dYLmZYNmew>? NUnad3BzOjV7NU[5PFg>
HUVEC M{TOW2Z2dmO2aX;uJGF{e2G7 NVjFRW17OTEEoN88US=> NFnQfHkyyqCq NFXNfHRFVVOR MXPpcoNz\WG|ZYRCpJRp\SCwdX3i[ZIh[W6mIHnueIVve2m2eTDv[kBndHWxcnXzZ4VvfCCjcnXhd{Bme3CnY3nhcIx6KGmwIIDldolvfWOuZXHyJJNx[WOn NEDzcI4zPTl3Nkm4PC=>
Caco-2 NVO5bnNMTnWwY4Tpc44hSXO|YYm= M1fjWlIvPSEQvF2= NGHYT3E{OCCvaX6= MXHheJRmdnWjdHXzJJRp\SCWR1[t{tIyNW2nZHnheIVlKGmwY4LlZZNmKGmwIGPFVnQh\nWwY4Tpc44> NGnN[nczPTl3NEmzNS=>
NRK M1\rd2Z2dmO2aX;uJGF{e2G7 MV[yNFDjiIWwZz;tcC=> Ml\YOQKBjWh? M4m2PGROW09? NVHNW5IxemW|Y4Xld{BucXSxdHnjJJBzd2e{ZYPzbY9v M2LlclI2QTR6NUi2
HeLa NXzpSW1UTnWwY4Tpc44hSXO|YYm= NXXNfItxOjBy4pEFcocwdWx? MmrhN{Bp NYH6SnROTE2VTx?= NHvqSZdqdmS3Y3XzJJRp\SCjcoTp[olkcWGuIHLy[YFsNXWyIH;mJJRp\SCJb3znbUBkd22ybHX4 MVSyOVk1QDV6Nh?=
COS MXTGeY5kfGmxbjDBd5NigQ>? M{\5RVEh|rypL33s M3PVdFMhcA>? NH63eY5kd22ybHX0[Yx6KGSrc4DldpNmeyC2aHWgRXAuOSC|aXfuZYzDqA>? M4DPZlI2QTF3OUCw
DF1  NIKzO3ZHfW6ldHnvckBCe3OjeR?= M1mzd|HDqM7:TdMg M1fVXVQ5KGh? NVqyTVFzTE2VTx?= NYXZZZp5\Gm|cHXyd4V{yqC2aHWg[Zhw\2Wwb4XzJGNUT2GuTlHjWFIheHKxdHXpci=> NFnXfoYzPThyN{C1OC=>
nHDFs  NXr1[mM4TnWwY4Tpc44hSXO|YYm= NX3LO41JOcLizszNxsA> NVzaPGtnOsLiaB?= NWrHc5k4eHKndnXueJMhfGinIHHzd4Vu[my7IH;mJIN6fG:|b3zpZ{Bkd2G2IIDyc5RmcW6|IH;ueI8hT2:uZ3mgcYVu[nKjbnXz MXeyOVc4OjZzNh?=
FRT  NHu4S3hHfW6ldHnvckBCe3OjeR?= M2PoR|Uh|rypL33s NIHNeHAzyqCq MYnicI9kc3NidILh[oZq[2urbnegeIhzd3WpaDD0bIUhT2:uZ3mgZ49ueGyneDDifUBqdmirYnn0bY5oKEWULYTvMWdwdGerIITyZY5{eG:{dB?= MnfjNlU4PjdzMUW=
FRT  NEf1dHJHfW6ldHnvckBCe3OjeR?= MkjwOUDPxGdxbXy= MoT1NuKhcA>? M4mye5Bz\X[nboTzJJRp\SCrbnPy[YF{\SCrbjDjcIVifmWmIN8xJJN2[nWwaYTzJJdp\W5iW17hL31qyqC5YYOgdoVlfWOnZB?= NVfOOGZSOjV5NkexNVU>
HepG2  NH6ySJJHfW6ldHnvckBCe3OjeR?= M2TBeVHjiIoEtV5CpC=> NUH4fIhIOjRiaB?= M{jzOGROW09? MkLz[IVkemWjc3XzJJRp\SCuZY\lcEBw\iCSWGKgcXJPSQ>? NY\jXllEOjV4MU[1PVc>
SMCs NXnkVnJvTnWwY4Tpc44hSXO|YYm= NFLnbooy|rypL33M NF6wNHk{KGh? NYDRTFZu[WOldX31cIF1\XNiQ17QXVIheHKxdHXpckBqdiC2aHWgSXIh[2:vcHHyeI1mdnRiYX7kJI5wKGyxbnfldkBkdy2ub3PhcIl7\WRid3n0bEB1cGViR3;s[4khdWG{a3XyxsA> Mlr1NlU2QDl2MkW=
OB-6 M{LoW2Fxd3C2b4Ppd{BCe3OjeR?= NFvPPIUzNjgEoN88US=> MXi0PEBp MXPpcoR2[2W|IHHwc5B1d3Orcx?= M1fMbFI2PTN{NEiw
iPSC-CMs  M2rwcWZ2dmO2aX;uJGF{e2G7 NEnLRmc2ODBibnevcYw> NUOybpBqPDhiaB?= NFPidnFqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kB1cGViaHnnbIVzKG2xYnnsbZR6KEyDTWDzJIF1KHSqZTDjc5N1KG:oIITo[UBtd3encjDtc4JqdGm2eTDzdIVkcWW| MWOyOVQ5QDZ4Nh?=
SP-Nluc MUHGeY5kfGmxbjDBd5NigQ>? NFOxZYI2KG2pL33M NFe2XFQ3KGh? NGfjbZhFVVORwrC= M1XzbINifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> NHjNfokzPTN7Mkm5PC=>
PEXEL-Nluc NUTRN49FTnWwY4Tpc44hSXO|YYm= NIDQVmw2KG2pL33M MVK2JIg> M1;rcGROW00EoB?= NIXNW|Jk[XW|ZYOgZY4hcW6lcnXhd4UhcW5icnXwc5J1\XJiYXP0bZZqfHliaX6geIhmKHCjcnHzbZRm NHPMW3QzPTN7Mkm5PC=>
H1299 M4j1N2Z2dmO2aX;uJGF{e2G7 Mm\LNVAh|rypL33s MViyOEBp NGCyb2FqdmS3Y3XzJIF2fG:yaHHnfeKh NG\Lc5kzPTN6OEm3NC=>
MDA-MB-231 MmXiR4VtdCCYaXHibYxqfHliQYPzZZk> MnrBNQKBmzVyIN88[{9uVA>? NUnBbHlFPDhiaB?= Mk\FSWM2OMLiPTCwMlAyPiEEtXevcWw> Mn\6NlU{PTZ3Nke=
MDA-MB-231 NUn0XIFzSXCxcITvd4l{KEG|c3H5 M3;X[VAvOSEQvHevcWw> MVu0JIg> NXv2WIJPcW6mdXPld{BieG:ydH;zbZM> MX[yOVM2PjV4Nx?=
MDA-MB-231 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOwMlAyNzBwMEWg{txoN22O M3LHPVI1KGh? M4S0W4lv[3KnYYPld{B1cGViZoLhZ5Rqd25ib3[gd5VjNUdzIHPlcIwh\GWkcnnz NXvjdmQ4OjV|NU[1Olc>
MDA-MB-231 NFm0d4hCeG:ydH;zbZMhSXO|YYm= NUnac4VrOC5yNfMAl|Eh|rypL33M NXzidXNNOjRiaB?= M3GzeIlv\HWlZYOgVGFTWCBqcH;sfUBCTFBvcnnic5NmKHCxbInt[ZJie2VvMTmgZ4xm[X[jZ3W= Mnu1NlU{PTZ3Nke=
MDA-MB-231 M{PvWGZ2dmO2aX;uJGF{e2G7 NGnibWYx6oDVNUCg{txoN22O NHm0S|IzPCCq NEPGWIRqdmirYnn0d{B1cGViZn;ycYF1cW:wIH;mJFNFKGGwZDCySEBkd2yxbnnldy=> NETXUVkzPTN3NkW2Oy=>
A172 MWTGeY5kfGmxbjDBd5NigQ>? NGrjSpcyOMLizsznM41t NFSwZ401yqCq MV3EUXNQyqB? MlTGdoV{fWy2czDpckB1cGVicnX0do9oemGmZTD0doFve3CxcoSgc4Yh\my3b4Lld4NmdnRiZ4LhcpVt\XN? MmrJNlUzOzl3MEe=
KMS-6 MVHGeY5kfGmxbjDBd5NigQ>? MlHnNeKh|ryPwrC= NGK0U5UzPCCq MVvlfIhq[mm2czDoZYxnKHSqZTDz[YNz\XSrb36gc4Yh\2GuYX7pck1NUSCjczDkbYQhfGinIHPvcpRzd2x? MWmyOVIzQTF{Nh?=
MEC M1\zXWZ2dmO2aX;uJGF{e2G7 MY[xJO69VQ>? MnTTNU42KGh? NGLqd4pk[XW|ZYOgZUBlemGvYYTpZ{Bl\WO{ZXHz[UBqdiC2aHWgd5Vz\mGlZTDWSWdHWjJ? NVPaVY02OjV{Mki4NVU>
HEK293/hERG NWrOXYZnTnWwY4Tpc44hSXO|YYm= Mme3NVDDqM7:TR?= NFXTfIMyyqCq MWTy[ZN2dHS|IHnuJIEhfGmvZT3k[ZBmdmSnboSgdoVlfWO2aX;uJI1ifHW{ZTDoSXJIKHC{b4TlbY7DqA>? NVXWb5NGOjV{MUi0Olk>
RBE4 M2jRN2Fxd3C2b4Ppd{BCe3OjeR?= NEDkR3AzyqEQvF2= MVqz5qCUOjUEoHi= NIjadnBqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHTldIVv\GWwdHz5 MXWyOVEzQDB{NR?=
RBE4 NFjQR2JHfW6ldHnvckBCe3OjeR?= MXGyxsDPxE1? NYHG[YRxO+LCk{K0xsBp NX7Ub4ZicW6lcnXhd4V{KHSqZTDYRnAyKHC{b4TlbY4hdGW4ZXzzJIFnfGW{IEOgZY5lKDcEoHigc4YhfHKnYYTt[Y51 MWKyOVEzQDB{NR?=
RBE4 M3rrSWZ2dmO2aX;uJGF{e2G7 M3zQOFLDqM7:TR?= NUOzTXJ3O+LCk{K0xsBp M1;2UYlv[3KnYYPld{Bi[3SrdnWgZ4F{eGG|ZT2xNkBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh Mn20NlUyOjhyMkW=
RBE4 NF31WHJHfW6ldHnvckBCe3OjeR?= NXr5XG06OsLizszN Mnn3N-KBmzJ2wrDo Ml7YbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUl;TJJRqdWVvZHXw[Y5l\W62bIm= NUTRPI55OjVzMkiwNlU>
RBE4 NHrs[5VHfW6ldHnvckBCe3OjeR?= MknXNuKh|ryP M4T3PFPjiJN{NNMgbC=> NVPGUnR7cW6mdXPld{BiKGSnbHH5[YQh\GWybHX0bY9vKG:oIITo[UBGWiCFYUKrxsBkd262ZX70JIF1KDcEoHigc4YhcW6ldXLheIlwdiC|aXfubYZq[2GwdHz5 NHXQeWozPTF{OECyOS=>
RBE4 MVLGeY5kfGmxbjDBd5NigQ>? NWT3cnlZOsLizszN NYO4cGNYO+LCk{K0xsBp NUHZZVVkcW6mdXPld{BidiCxdnXycI9i\CCxZjDDZVIsyqCrbjD0bIUhdWm2b3Poc45lemmjIHnuJJRp\SCoaYLzeEA3yqCqIH;mJIlv[3WkYYTpc44hMHEkgJm85qCKOC5yMEGpJIJ2fCCFYUKrxsBt\X[nbIOgbY4hfGirczDvdodidmWubHWg[IVkemWjc3XkJIFnfGW{IEGyxsBpKG:oIHnuZ5Vj[XSrb36= NIXFWZYzPTF{OECyOS=>
Huh-7  MXrGeY5kfGmxbjDBd5NigQ>? MlPjNe69\y:vTB?= NV7E[GpDO+LCk{K0xsBp M3vKO4lv[3KnYYPld{B1cGVibHX2[Ywhd2ZiQWDFNUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NX\B[opjOjVyMk[xO|Q>
HepG2  MojHSpVv[3Srb36gRZN{[Xl? Ml2yNe69\y:vTB?= NI\rPHo{6oDVMkVCpIg> NIO4S|BqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MU[yOVAzPjF5NB?=
H838-LKB1 NEDMUo1HfW6ldHnvckBCe3OjeR?= NHXLcZA{OMLibnevcYw> NEXsPXUyOi9zODDo MX;pcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKEKrUNMg MnzVNlUxOTFyOEK=
H838-KDLKB1  M3PQS2Z2dmO2aX;uJGF{e2G7 NX3mVpBmOzEEoH7nM41t MXKxNk8yQCCq M33XPYlv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiQnnQxsA> M4PpeFI2ODFzMEiy
H838-KDLKB1  NY\HWlVOTnWwY4Tpc44hSXO|YYm= MWKzNOKhdmdxbXy= M{jlcFEzNzF6IHi= NInQOYZqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDwbI9{eGixconsZZRm\CCnSV[y{tEhMHCqb4PwbI8u\UmIMt8xLS=> NWLpN3dFOjVyMUGwPFI>
3T3-L1 NHrIbZFHfW6ldHnvckBCe3OjeR?= M3PqZ|Uh|rypL33s MX6zNEBucW5? NUXnN3U{dWmvaXPzJJRp\SCnZn\lZ5R{KG:oIHnud5VtcW5iYX7kJINifXOnczDyc4J2e3RicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEApW2W{IES3N{kh[W6mIIDoc5NxcG:{eXzheIlwdiCxZjDBV|E3OCBqVHjyJFY1OiCjbnSgV4VzKDV6ODm= NFvmTYQzPDh2M{iyOy=>
3T3-L1 NGPtRplHfW6ldHnvckBCe3OjeR?= NFWyZ2c2KM7:Zz;tcC=> M1nUSFMxKG2rbh?= NV2zUpRjemWlYYDpeJVt[XSnczDpcpN2dGmwIHHjeIlwdiC5aYToJJJme3CnY4SgeI8hemWpdXzheIlv\yCDa4SgZYN1cX[rdImgZY5lKEGVMU[wJJBpd3OyaH;yfYxifGmxbh?= M2rneFI1QDR|OEK3
3T3-L1 MVHGeY5kfGmxbjDBd5NigQ>? MYe1JO69\y:vbB?= NITXR3o{OCCvaX6= NUn0OIxo[2G3c3XzJJJmfmW{c3nicIUhemWmaYP0doljfXSrb36gc4YhT0yXVES= NX65OXp6OjR6NEO4Nlc>
3T3-L1 Ml:0SpVv[3Srb36gRZN{[Xl? MofmOUDPxGdxbXy= NUHydYh5OcLiaB?= NX\WXHdj[2G3c3XzJJJm\Gm|dILpZpV1cW:wIH;mJGdNXVR2IHL1eEBvd3RiaX7jdoVie2ViaX6g[4x2[2:|ZTD1dJRic2V? NYPxcZVEOjR6NEO4Nlc>
3T3-L1 M{Lp[WZ2dmO2aX;uJGF{e2G7 Mof5OUDPxGdxbXy= MonyNeKhcA>? MYDjZZV{\XNicHjvd5Bpd3K7bHH0bY9vKG:oIITo[UBHd3iRMTD0doFve2O{aYD0bY9vKG[jY4Tvdi=> NF;COIwzPDh2M{iyOy=>
HeLa  NF;xd5VHfW6ldHnvckBCe3OjeR?= NUOwWndEPSEQvHevcYw> NV7UVII5OyCq NWLDVlRu[2G3c3XzJI52[2ynYYKg[ZhkdHW|aX;uJI9nKHSqZTDGc5hQOSC2cnHud4NzcXC2aX;uJIZi[3SxcjDhcoQh\GWlcnXhd4V{KHS{YX7zZ5JqeHSrb36gc4YhTm:6T{GtdoVofWyjdHXkJIdmdmW| MXiyOFg1Ozh{Nx?=
HEK293 Ml6wSpVv[3Srb36gRZN{[Xl? NIP4S4Y2yqEQvHevcYw> MWWxNuKhcA>? M3zke4Fjd2yrc3jld{BEVUFvaX7keYNm\CCFUlXMSFIhe2WlcnX0bY9v MXiyOFY5PzR|MR?=
COS-1 NXXLW25STnWwY4Tpc44hSXO|YYm= MV61JOK2\y:vbB?= M{K4TlI1KGkEoB?= M1nLSZJme3S{aXP0d{Btd2OjbHn6ZZRqd25ib3[gUmIhcW5idHjlJJBmemmwdXPs[YFzKHKnZ3nvcuKh NY\UUJdKOjR4N{G3OVE>
PRP MWPGeY5kfGmxbjDBd5NigQ>? M{fTZVExKM7:TR?= MWnhZpJw\2G2ZYOgV2RHNTIQsT3t[YRq[XSnZDDDXGNTPyCneITldo5idGm8YYTpc47DqA>? NGDPepkzPDZ4OEe1NC=>
RAW264.7 M{L5NWFxd3C2b4Ppd{BCe3OjeR?= MYq0JO69VQ>? NVv4S4o5PDhiaB?= MmfRZZR1\W63YYTld{B1cGViaX7obYJqfGmxbjDv[kBwgC2ORFytbY5lfWOnZDDhdI9xfG:|aYOgZY5lKHSqZTDmZYNqdGm2YYTpc44hd2ZiY3jvcIV{fGW{b3yg[YZndHW6IHL5JGFkNWiHLUG4RU1PUDJ? NYXO[Fg2OjR4M{mwN|I>
MDMs NXS2bJBWSXCxcITvd4l{KEG|c3H5 NUjBS44xOTEkgJpOwIcwdWx? NYTldWdiOTJxMUWgbC=> NYfOUGIycW6mdXPld{BieG:ydH;zbZM> Ml\5NlQ2PTZ4OUW=
PMHs  NX3he5hUTnWwY4Tpc44hSXO|YYm= NUjuOI41OTEkgKOyNQKBkc7:Zz;tcC=> M1G1cFI16oDLaB?= MmS1SG1UVw>? NU[zSFhocW6mdXPl[EBGWiC|dILld5M> NFL0WWczPDRyN{K0Ni=>
PMHs  NUizWpJESXCxcITvd4l{KEG|c3H5 MYSxNQKBmzJy4pEJ{txoN22u MWiyOQKBkWh? MUXEUXNQ MlT1bY5kemWjc3XzJINmdGxiZHXheIg> MknHNlQ1ODd{NEK=
HEK293/tau MVHGeY5kfGmxbjDBd5NigQ>? NILabo82KM7:TR?= MnzqNU8zNzRiaB?= MUfpcoR2[2W|IFfvcIdqKG[{YXft[Y51[XSrb39CpC=> NWjPUIw4OjR|NkiwPFk>
HEK293/tau MmD3SpVv[3Srb36gRZN{[Xl? MnizOUDPxE1? MW[zJIg> NVziUW5mcW6mdXPld{B1[XViaInw[ZJxcG:|cHjvdplt[XSrb36= MUGyOFM3QDB6OR?=
ADF NWTaRZNJTnWwY4Tpc44hSXO|YYm= MVqxNEDPxE1? M1;PVlE3KGh? M2e0dYlvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV NF7FVJozPDJ{OEKzNi=>
U373  MWPGeY5kfGmxbjDBd5NigQ>? M3HjflExKM7:TR?= M3XXT|E3KGh? NYPSNWd[cW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? NGrpVJgzPDJ{OEKzNi=>
RKO-HIPK2i NH7uempHfW6ldHnvckBCe3OjeR?= NGHMblcyOCEQvF2= NWThZlU2OTZiaB?= NVezb5pzcW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? MXOyOFIzQDJ|Mh?=
ADF  M{XCc2Z2dmO2aX;uJGF{e2G7 NYrwOndiOTBizszNxsA> MWq2JIg> Mlr1bY1x[Wm{czD0bIUhTENiYXP0bZZifGmxbh?= NEPtWWMzPDJ{OEKzNi=>
Huh7 M3zvfWZ2dmO2aX;uJGF{e2G7 NV7xS3RwPSEQvHevcYw> NEH3PIo1KGh? MlPFZYJwdGm|aHXzJJRp\SC|ZXPy[ZRqd25ib3[gJIlvfHKjY3XscJVt[XJiQYDvRi=> MmLpNlQyODBzNEC=
Huh7 MV;GeY5kfGmxbjDBd5NigQ>? MmfFOUDPxGdxbXy= M3O2ZlEhcA>? MoHGZ4F2e2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5iQYDvRk1kemW|Y3XueJM> M2fL[FI1OTByMUSw
Huh7 MXnGeY5kfGmxbjDBd5NigQ>? MnXxOgKBmzFywrDu[{9udA>? MkD4NVIhcA>? NFG1ZlZqdmO{ZXHz[ZMhSXCxQj3jdoV{[2WwdIOge4l1cG:3dDDpcohq[mm2aX7nJJNm[3KndHnvci=> NYXZRWt7OjRzMECxOFA>
BAECs M{LnNmZ2dmO2aX;uJGF{e2G7 MV61JO69\y:vbB?= MYiwMVQhcA>? NVXaNFMxcW6mdXPld{B1cGVicnHwbYQh\GWyaH;zdIhwenmuYYTpc44hd2ZiZV7PV{BifCCVZYKxNVc6 Mo[5NlQxQDV{MkW=
Macrophages Mn\ISpVv[3Srb36gRZN{[Xl? NEfHeGY4OSEEtV2= Mmi1OkBp NFXueHlqdmirYnn0d{BtfW6jc3nuJIlvfGW{bnHsbZpifGmxbtMg MoLaNlQxOzl5NEC=
Colo 205 M4rQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojQNE02KM7:Zz;tUC=> NY[2XIF1PDhiaB?= NYDMbYJ5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gd5V{eGWwc3nvckBkfWy2dYLld{B4cXSqIHHuJIV{fGmvYYTl[EBKSzVyIH;mJJ4yPSCwZz;tUC=> MmTDNlM6PzN7OU[=
Colo 205 NEfkS41HfW6ldHnvckBCe3OjeR?= NUHRRWFYOC5yMUKtNE4xOjVizsznM41N NV\xbHp[OTRiZB?= MXvy[YR2[2W|IITo[UBkdG:wb3flcolkcXS7IH;mJGNwdG9iMkC1JGNUS3N? NE\QfnMzOzl5M{m5Oi=>
Colo 205 MmHBRZBweHSxc3nzJGF{e2G7 NHTnZZcxNjFizsznM41N MYSwMVI1KGh? M4HacIlv\HWlZYOgZZBweHSxc3nzJI9nKEOxbH:gNlA2KGOnbHzzJIlvKHO3c4DlcpNqd25iY4XseJVz\XN? MYWyN|k4Ozl7Nh?=
Colo 205 MkfhSpVv[3Srb36gRZN{[Xl? NIjzcXMxNjBzNTFOwIcwdUx? NWHyVnVMOjRiaB?= NHqxVY5qdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGVTKHO2cnXzd{1z\WyjdHXkJIdmdmW| MWKyN|k4Ozl7Nh?=
Colo 205 NVHVUo9CTnWwY4Tpc44hSXO|YYm= Mk\DNE4xOTVizsznM41N Ml7xNlQhcA>? MnnVbY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIF3NVJM> MmjRNlM6PzN7OU[=
IBRS2 M4\k[2Z2dmO2aX;uJGF{e2G7 Ml7COUDPxGdxbXy= NIS4boMxNjViaB?= NELRT2dFVVOR MUHkbZNzfXC2czD0bIUhTVKJSVOgZY5lKEexbHfpxsA> NXHZO2pCOjN7NkO1N|Q>
IBRS2 NFHQfm9HfW6ldHnvckBCe3OjeR?= NGPnUZc2KM7:Zz;tcC=> NWi0emFoOC53IHi= NUfqOmVXTE2VTx?= NGfOfFhmdmijbnPld{BHVUSYIHnu[oVkfGmxbh?= M1O3T|I{QTZ|NUO0
HeLa NVLoXVE6TnWwY4Tpc44hSXO|YYm= M1;5XVIh|ryP NHPNTFkzKGkEoB?= NGTkR4lifHSnboXheIV{KHSqZTDUUmYucW6mdXPl[EB{\WO{ZYTpc44hd2ZiSVytNVU> MVmyN|k2ODh7Mh?=
HFS  M{nwNWZ2dmO2aX;uJGF{e2G7 MUewMVEh|rypL33s NWC0XWdsOjRiaB?= NUH1O|N1T0yWUDDlfJBz\XO|aX;uJJJm[WOqZYOgZUBxdGG2ZXH1JIF1KGOxbnPlcpRz[XSrb37zJIF{KGyxdzDhd{AxNjBzINM1[{9udA>? M1zlR|I{QDl2NkOz
HFS  M4fzOWZ2dmO2aX;uJGF{e2G7 NEW2[YUxNjBzINM1[{9udA>? NVnE[lM5OjRiaB?= NX7jcnFCcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGeueXPvd5BpcW6pb3zpdIllKHO7boToZZNmKGenbnXzJIF1KDZiaB?= M3TPRlI{QDl2NkOz
OVCAR-3 M4jvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XDZVHjiJNzNdMg{txOyqB? NVe5THhUOjUEoHi= MYfpcoR2[2W|IHGgcI9{eyCxZjDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6yqB? MnnFNlM5OjZ7NkS=
OVCAR-3 MoD1SpVv[3Srb36gRZN{[Xl? NGm2TYwy6oDVMUZCpO69VcLi Mk\INlTDqGh? M3T4Solv\HWlZYOgcpVkdGWjcjDkZY1i\2V? M4H1SFI{QDJ4OU[0
OVCAR-3 NWnTeGdVSXCxcITvd4l{KEG|c3H5 NVWyc2FSOS1zMNMg{txO MXe0JIg> M4q4PIlv\HWlZYOgeIhmKGGldHn2ZZRqd25ib3[gZZBweHSxc3nzMZJmdGG2ZXSgdJJwfGWrboO= NGfyUWgzOzh{Nkm2OC=>
OVCAR-3 NHfPTYhCeG:ydH;zbZMhSXO|YYm= NG\z[3UyOMLizszN NFjTToozPMLiaB?= NXXaOHUzcW6mdXPld{Bi[3SrdnH0bY9vKG:oIHPhd5Bie2W| MUKyN|gzPjl4NB?=
OVCAR-3 MYfGeY5kfGmxbjDBd5NigQ>? NVj1[mR5OeLCk{GwxsDPxE1? M3PLWVI1yqCq M3TveYlv\HWlZYOg[Il{enWydHnvckBw\iC2aHWgcYl1d2Oqb37kdolidCC2cnHud41mdWK{YX7lJJBwfGWwdHnhcC=> MVSyN|gzPjl4NB?=
OVCAR-3 NGXyOHdHfW6ldHnvckBCe3OjeR?= MljJNgKBmzFywrFOwG0> MWKyOOKhcA>? Ml\UbY5lfWOnczDmc5Ju[XSrb36gc4YhemWjY4TpeoUhd3i7Z3XuJJNx\WOrZYO= NVTwdmI5OjN6Mk[5OlQ>
OVCAR-3 M3vORWZ2dmO2aX;uJGF{e2G7 MkP1NgKBmzFywrFOwG0> MnvSNlTDqGh? NELYc2dqdmirYnn0d{Bk\WyuIHHkbIV{cW:wIHHu[EBucWe{YYTpc44> MoDPNlM5OjZ7NkS=
MKN45 M33aNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorWTWM2ODxyLkCwNUDPxGdxbXy= NXG4bHdYOjN5OUOzOFI>
LOVO MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\xRmlEPTB;MD6xNkDPxGdxbXy= M4mxVlI{Pzl|M{Sy
A549 NFvqVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LWT2lEPTB;MD6wOEDPxGdxbXy= M{T5bVI{Pzl|M{Sy
MDA-MB-435 NITpUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHYXYkzUUN3MEywMlAxOSEQvHevcYw> MWOyN|c6OzN2Mh?=
HepG2 NYLsXlhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXVTIRNUUN3MEywMlAxOSEQvHevcYw> MkGxNlM4QTN|NEK=
HL-60 NFLXXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Tpc2lEPTB:MD6wNFEh|rypL33s NVTvUpQ1OjN5OUOzOFI>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:

[5]

+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID